Corrigendum to "Simulating Radiotherapy Effect in High-Grade Glioma by Using Diffusive Modeling and Brain Atlases".

[This corrects the article DOI: 10.1155/2012/715812.].

A Proposed Paradigm Shift in Initializing Cancer Predictive Models with DCE-MRI Based PK Parameters: A Feasibility Study.

Glioblastoma multiforme is the most aggressive type of glioma and the most common malignant primary intra-axial brain tumor. In an effort to predict the evolution of the disease and optimize therapeutical decisions, several models have been proposed for simulating the growth pattern of glioma. One of the latest models incorporates cell proliferation and invasion, angiogenic net rates, oxygen consumption, and vasculature.

Employing in-vivo molecular imaging in simulating and validating tumor growth.

During the last decades, especially via the EU initiative related to the Virtual Physiological Human, significant progress has been made in advancing "in-silico" computational models to produce accurate and reliable tumor growth simulations. However, currently most attempts to validate the outcome of the models are either done in-vitro or ex-vivo after tumor resection. In this work, we incorporate information provided by fluorescence molecular tomography performed in-vivo into a mathematical model that describes tumor growth.

Simulating radiotherapy effect in high-grade glioma by using diffusive modeling and brain atlases.

Applying diffusive models for simulating the spatiotemporal change of concentration of tumour cells is a modern application of predictive oncology. Diffusive models are used for modelling glioblastoma, the most aggressive type of glioma. This paper presents the results of applying a linear quadratic model for simulating the effects of radiotherapy on an advanced diffusive glioma model.

Clinically driven design of multi-scale cancer models: the ContraCancrum project paradigm.

The challenge of modelling cancer presents a major opportunity to improve our ability to reduce mortality from malignant neoplasms, improve treatments and meet the demands associated with the individualization of care needs. This is the central motivation behind the ContraCancrum project. By developing integrated multi-scale cancer models, ContraCancrum is expected to contribute to the advancement of in silico oncology through the optimization of cancer treatment in the patient-individualized context by simulating the response to various therapeutic regimens.